Navigation Links
Sorrento Therapeutics Awarded NIH Grant for MRSA Program
Date:5/21/2010

SAN DIEGO, May 21 /PRNewswire-FirstCall/ -- Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced that it has received an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Institute of Allergy and Infectious Diseases. The peer-reviewed grant was awarded to support the Company's program to generate and develop novel antibody therapeutics and vaccines to combat Staphylococcus aureus (S. aureus or "Staph") infections, including methicillin-resistant S. aureus (MRSA), by disrupting quorum sensing, a bacterial communication process essential to virulence. The Phase I grant is for $300,000 annually for two years, with the possibility of Phase II funding of $1 million per year for up to 3 years.

"It is clear that the NIH is highly motivated to fund novel approaches to tackling the serious healthcare burden of MRSA. We believe our program to develop potential vaccines and antibody therapeutics against MRSA holds great clinical promise because of the high morbidity and mortality caused by this pathogen and the limited treatment options available today," said Antonius Schuh, Ph.D., Chairman and Chief Executive Officer of Sorrento Therapeutics.

Sorrento Therapeutics' MRSA program targets specific auto-inducing peptides (AIPs) central to the quorum sensing system of S. aureus, which induces bacterial virulence. Masking these AIPs leads to a disruption of bacterial communication ("quorum quenching") and suppresses virulence. In recommending the grant application for funding, expert panel reviewers noted that targeting quorum sensing and the virulence factors of S. aureus represented a paradigm shift, which could result in fewer side effects than conventional drug therapies. Th
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014   Vestagen Technical Textiles, ... patient experience at hospitals. The myComfort™ line of patient ... barrier fabric that is fluid repellant, breathable and in ... the growth of bacteria on the fabric i . ... plays in the chain of transmission. We want myComfort ...
(Date:9/16/2014)... 2014 The Lupus Foundation of America and ... today released results from UNVEIL: understanding the impact of ... lupus journey and the challenges not only for those ... UNVEIL study, which involved over 1,000 people with lupus ... on all aspects of life including family, work, finances, ...
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. ... dedicated to delivering high quality and novel medicines to ... Chief Executive Officer Mark Baum will be ... Alpha Select Conference in New York City.  Mr. Baum ... Go Dropless™ campaign in ophthalmology. The presentation is scheduled ...
Breaking Medicine Technology:New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... and radiation therapy as part of breast conservation ... with hormone-receptor positive (HR+) invasive breast cancer. A ... Center, however, shows that combination may not be ... , The results, which Fox Chase researchers ... 56th Annual Meeting on Sunday, September 14, suggest ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... As part of its Latinos Living ... (LULAC) will host the second annual health festival in ... free health screenings for osteoporosis, HIV, and high blood ... cholesterol levels as well as bone marrow typing. In ... 6 years old , The event will also feature ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, ... U.S. cancer survivors are alive today, compared to just ... Research reported Tuesday. These individuals amount to 4 ... of childhood cancer, according to the association,s annual progress ... and treatment of cancer and details some of the ...
Breaking Medicine News(10 mins):Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... that combines 2 medications , , SUNDAY, March 30 (HealthDay News) ... make sense of a trial showing that a drug can ... apparent benefit to people at high risk of heart attack ... well-known statin -- simvastatin -- with ezetimibe, which also lowers ...
... use with angioplasty following a heart attack, the anticoagulants ... measures within 90 minutes after the procedure, while patients ... a lower risk of major adverse cardiac events within ... to a JAMA study being released early online March ...
... risk and don,t increase mortality probability , , SUNDAY, March ... placed in diseased coronary arteries to keep them open, ... patients, new research shows. , In the largest study ... the drug in question retards the growth of arterial ...
... to Join Nation,s Largest RN ... Organization, ... registered nurses to have a stronger voice to speak,out for patients and ... to win union collective bargaining,rights., RNs at Cypress Fairbanks Medical Center ...
... deaths could be avoided with lifestyle changes, experts say, ... that could cut cancer deaths in half. , Well, ... American Cancer Society report that said as many as ... lifestyle changes, such as quitting smoking, maintaining a healthy ...
... mice was important protective mechanism, researchers say , , FRIDAY, March ... a critical role in protecting the heart during a heart ... It was already known that Gi increased activity in a ... helping the heart adapt to damage or if it actually ...
Cached Medicine News:Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:Key Protein Limits Damage of Heart Attack 2
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Mayo dissecting scissors with beveled blades....
Ribbon malleable, general purpose retractor....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
Medicine Products: